Bristol Myers Squibb (CELG-RI) Total Current Liabilities (2009 - 2026)

Bristol Myers Squibb has disclosed Total Current Liabilities across 18 years of filings, most recently posting $19.2 billion for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 20.41% year-over-year to $19.2 billion; the TTM figure through Mar 2026 stood at $19.2 billion (down 20.41% YoY), while the FY2025 annual figure was $23.4 billion, down 1.5% from the prior year.
• Total Current Liabilities fell to $19.2 billion in Q1 2026, from $23.4 billion in the prior quarter.
• Over the last five years, Total Current Liabilities for CELG-RI reached as high as $28.1 billion in Q3 2025 and fell as low as $18.9 billion in Q3 2022.
• The 5-year median for Total Current Liabilities is $22.8 billion (2022), against an average of $22.8 billion.
• Annual changes were most pronounced in 2024 — Total Current Liabilities soared 35.3% — and 2026, when it fell 20.41%.
• A 5-year view of Total Current Liabilities shows it stood at $21.9 billion in 2022, then climbed by 1.7% to $22.3 billion in 2023, then gained by 6.79% to $23.8 billion in 2024, then retreated by 1.5% to $23.4 billion in 2025, then retreated by 18.19% to $19.2 billion in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $19.2 billion, $23.4 billion, and $28.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.